Ion channel gene therapy for smooth muscle disorders: Relaxing smooth muscles to treat erectile dysfunction

Jonathan D. Schiff, Arnold Melman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The promise of gene therapy to treat diseases remains largely unfulfilled. Past setbacks and the complexity of the delivery systems used, in terms of both targeting the appropriate cells and inducing expression of products at therapeutic levels, thus far have prevented significant success for gene therapy. Smooth muscle disorders represent a unique target for gene therapy. In many cases, smooth muscle is readily accessible and, to induce a therapeutic effect, will not require very high levels of gene product expression. This allows a lower efficiency of gene transfer to be successful. With these important features in mind, we believe that naked DNA transfer of potassium ion channels represents a novel and successful way to treat smooth muscle disorders. Herein, we present a rationale for treating erectile dysfunction, a smooth muscle disorder of the cavernosal bodies of the penis, with naked DNA gene transfer therapy. By inserting the hSlo gene, which codes for Maxi-potassium channels, into smooth muscle cells, we can improve smooth muscle relaxation in the corporal bodies and thus improve erectile function. This method of gene transfer has proven to be safe and effective for erectile dysfunction, and human trials are ongoing.

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
JournalAssay and Drug Development Technologies
Volume4
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Muscular Diseases
Erectile Dysfunction
Ion Channels
Genetic Therapy
Smooth Muscle
Potassium Channels
Genes
Muscle Relaxation
Penis
Therapeutic Uses
Smooth Muscle Myocytes
Gene Expression
DNA

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Ion channel gene therapy for smooth muscle disorders : Relaxing smooth muscles to treat erectile dysfunction. / Schiff, Jonathan D.; Melman, Arnold.

In: Assay and Drug Development Technologies, Vol. 4, No. 1, 02.2006, p. 89-95.

Research output: Contribution to journalArticle

@article{627b57c3ad234769b77da77c7639d093,
title = "Ion channel gene therapy for smooth muscle disorders: Relaxing smooth muscles to treat erectile dysfunction",
abstract = "The promise of gene therapy to treat diseases remains largely unfulfilled. Past setbacks and the complexity of the delivery systems used, in terms of both targeting the appropriate cells and inducing expression of products at therapeutic levels, thus far have prevented significant success for gene therapy. Smooth muscle disorders represent a unique target for gene therapy. In many cases, smooth muscle is readily accessible and, to induce a therapeutic effect, will not require very high levels of gene product expression. This allows a lower efficiency of gene transfer to be successful. With these important features in mind, we believe that naked DNA transfer of potassium ion channels represents a novel and successful way to treat smooth muscle disorders. Herein, we present a rationale for treating erectile dysfunction, a smooth muscle disorder of the cavernosal bodies of the penis, with naked DNA gene transfer therapy. By inserting the hSlo gene, which codes for Maxi-potassium channels, into smooth muscle cells, we can improve smooth muscle relaxation in the corporal bodies and thus improve erectile function. This method of gene transfer has proven to be safe and effective for erectile dysfunction, and human trials are ongoing.",
author = "Schiff, {Jonathan D.} and Arnold Melman",
year = "2006",
month = "2",
doi = "10.1089/adt.2006.4.89",
language = "English (US)",
volume = "4",
pages = "89--95",
journal = "Assay and Drug Development Technologies",
issn = "1540-658X",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Ion channel gene therapy for smooth muscle disorders

T2 - Relaxing smooth muscles to treat erectile dysfunction

AU - Schiff, Jonathan D.

AU - Melman, Arnold

PY - 2006/2

Y1 - 2006/2

N2 - The promise of gene therapy to treat diseases remains largely unfulfilled. Past setbacks and the complexity of the delivery systems used, in terms of both targeting the appropriate cells and inducing expression of products at therapeutic levels, thus far have prevented significant success for gene therapy. Smooth muscle disorders represent a unique target for gene therapy. In many cases, smooth muscle is readily accessible and, to induce a therapeutic effect, will not require very high levels of gene product expression. This allows a lower efficiency of gene transfer to be successful. With these important features in mind, we believe that naked DNA transfer of potassium ion channels represents a novel and successful way to treat smooth muscle disorders. Herein, we present a rationale for treating erectile dysfunction, a smooth muscle disorder of the cavernosal bodies of the penis, with naked DNA gene transfer therapy. By inserting the hSlo gene, which codes for Maxi-potassium channels, into smooth muscle cells, we can improve smooth muscle relaxation in the corporal bodies and thus improve erectile function. This method of gene transfer has proven to be safe and effective for erectile dysfunction, and human trials are ongoing.

AB - The promise of gene therapy to treat diseases remains largely unfulfilled. Past setbacks and the complexity of the delivery systems used, in terms of both targeting the appropriate cells and inducing expression of products at therapeutic levels, thus far have prevented significant success for gene therapy. Smooth muscle disorders represent a unique target for gene therapy. In many cases, smooth muscle is readily accessible and, to induce a therapeutic effect, will not require very high levels of gene product expression. This allows a lower efficiency of gene transfer to be successful. With these important features in mind, we believe that naked DNA transfer of potassium ion channels represents a novel and successful way to treat smooth muscle disorders. Herein, we present a rationale for treating erectile dysfunction, a smooth muscle disorder of the cavernosal bodies of the penis, with naked DNA gene transfer therapy. By inserting the hSlo gene, which codes for Maxi-potassium channels, into smooth muscle cells, we can improve smooth muscle relaxation in the corporal bodies and thus improve erectile function. This method of gene transfer has proven to be safe and effective for erectile dysfunction, and human trials are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=33645321398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645321398&partnerID=8YFLogxK

U2 - 10.1089/adt.2006.4.89

DO - 10.1089/adt.2006.4.89

M3 - Article

C2 - 16506893

AN - SCOPUS:33645321398

VL - 4

SP - 89

EP - 95

JO - Assay and Drug Development Technologies

JF - Assay and Drug Development Technologies

SN - 1540-658X

IS - 1

ER -